Medicare Rx medication therapy management
Executive Summary
Centers for Medicare & Medicaid Services sets 2006 "cost threshold" for Medicare beneficiaries targeted for medication therapy management services under Part D benefit. Patient drug spending must be "likely to exceed" $4,000 a year for multiple chronic diseases. Overall, CMS is giving Medicare drug plans free rein in implementing required medication therapy management programs (1"The Pink Sheet" Feb. 7, 2005, p. 21)...
You may also be interested in...
Medication Therapy Management Standards Will Be Set In Practice, Not Regs
The Centers for Medicare & Medicaid Services will give Part D plans free rein in implementing required medication therapy management programs
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.